CCL3 and Alzheimer disease: However, this difference was comparable between AD-PBMCs treated with CSF, IL-8, MIP-1α and PBS (Fig. 4e), suggesting that AD-PBMCs are more vulnerable to environment changes such as transferring cells to an in vitro environment or possibly from the peripheral blood to the CSF.